Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

No clear link between paracetamol in pregnancy and autism/ADHD

Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...

Light at night can increase heart disease risk

Being exposed to bright light at night can significantly increase your chances of developing...

Scientists find new driver of ovarian cancer spread

A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...

Content from other channels on our network

Engineers Australia CEO calls for action to address engineering shortages

Victorian Government funding safer manufacturing workplaces

Major Korean steelmaker joins HILT CRC

WA Government wants its projects to be built with local green steel

ASC selects Siemens software for Collins Class submarines

Concrete repair key to sustainability

Signposting the way to a regenerative economy

Pledges favour land-based carbon removal over emission cuts

Epson opens smart factory with Citizen Wolf

MSCI report shows rising climate risks

How are AI models approved for use in health care?

$910m new Rouse Hill Hospital — designs released

What is My Health Record? For healthcare providers

Nurse turns to teaching health care's next generation

Doctors criticise "risky prescribing agenda"